You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 49 No. 10, October 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  OBSERVATIONS
 This Article
 •References
 •Full text PDF
 •Correction
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Central Nervous System Involvement in the Eosinophilia-Myalgia Syndrome

Joanne Lynn, MD; Kottil W. Rammohan, MD; Robert A. Bornstein, PhD; John T. Kissel, MD

Arch Neurol. 1992;49(10):1082-1085.


Abstract

• A patient with eosinophilia-myalgia syndrome developed progressive central nervous system involvement that did not improve despite discontinuation of L-tryptophan therapy. Neurologic impairment was manifested initially by spastic monoparesis, which was improved by treatment with methylprednisolone and hydroxyurea. Recurrence of weakness was accompanied by gait ataxia, dysphagia, and complaints of a gradual decline in memory and concentration. Neuropsychological testing identified a broad pattern of cognitive deficits suggestive of a subcortical dementia, and magnetic resonance imaging demonstrated multiple high-signal lesions in the white matter. Cognitive deficits appear to be underrecognized in patients with the eosinophilia-myalgia syndrome. The response of our patient's initial symptoms to corticosteroid therapy suggests a possible role for autoimmune mechanisms in the pathogenesis of central nervous system involvement in the eosinophilia-myalgia syndrome. Neuropsychological evaluation should be performed in patients with cognitive complaints to delineate the full spectrum of central nervous system impairment associated with the eosinophilia-myalgia syndrome.



Author Affiliations

From the Departments of Neurology (Drs Lynn, Rammohan, and Kissel) and Psychiatry (Dr Bornstein), Ohio State University College of Medicine, Columbus.


Footnotes

Accepted for publication April 29, 1992.

Reprint requests to Department of Neurology, Ohio State University College of Medicine, 1654 Upham Dr, Columbus, OH 43210 (Dr Lynn).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pain, Fatigue, and Sleep in Eosinophilia-Myalgia Syndrome: Relationship to Neuropsychological Performance
Pollina et al.
J. Neuropsychiatry Clin. Neurosi. 1998;10:338-342.
ABSTRACT | FULL TEXT  

Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings
Armstrong et al.
J. Neurol. Neurosurg. Psychiatry 1997;63:633-641.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.